365 related articles for article (PubMed ID: 12428224)
1. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
[TBL] [Abstract][Full Text] [Related]
2. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
[TBL] [Abstract][Full Text] [Related]
3. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
4. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
5. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Landewé RB; Boers M; Verhoeven AC; Westhovens R; van de Laar MA; Markusse HM; van Denderen JC; Westedt ML; Peeters AJ; Dijkmans BA; Jacobs P; Boonen A; van der Heijde DM; van der Linden S
Arthritis Rheum; 2002 Feb; 46(2):347-56. PubMed ID: 11840436
[TBL] [Abstract][Full Text] [Related]
6. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
Mod Rheumatol; 2009; 19(3):273-82. PubMed ID: 19452245
[TBL] [Abstract][Full Text] [Related]
7. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis.
Landewé RB; Geusens P; van der Heijde DM; Boers M; van der Linden SJ; Garnero P
Ann Rheum Dis; 2006 Jan; 65(1):40-4. PubMed ID: 16126801
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.
Boers M; Kostense PJ; Verhoeven AC; van der Linden S;
Arthritis Rheum; 2001 Oct; 44(10):2242-6. PubMed ID: 11665964
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
Garnero P; Ayral X; Rousseau JC; Christgau S; Sandell LJ; Dougados M; Delmas PD
Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
11. Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis.
Christensen AF; Lottenburger T; Lindegaard H; Christgau S; Hørslev-Petersen K; Junker P
Clin Exp Rheumatol; 2009; 27(2):307-14. PubMed ID: 19473573
[TBL] [Abstract][Full Text] [Related]
12. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
[TBL] [Abstract][Full Text] [Related]
13. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
14. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
[TBL] [Abstract][Full Text] [Related]
15. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
Jansen NW; Roosendaal G; Lundin B; Heijnen L; Mauser-Bunschoten E; Bijlsma JW; Theobald M; Lafeber FP
Arthritis Rheum; 2009 Jan; 60(1):290-8. PubMed ID: 19116938
[TBL] [Abstract][Full Text] [Related]
16. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
Marotte H; Gineyts E; Miossec P; Delmas PD
Ann Rheum Dis; 2009 Jul; 68(7):1197-200. PubMed ID: 18713784
[TBL] [Abstract][Full Text] [Related]
17. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
18. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Smolen JS; Van Der Heijde DM; St Clair EW; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Schiff M; Baker D; Han C; Han J; Bala M;
Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
[TBL] [Abstract][Full Text] [Related]
19. Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis.
Vosse D; Landewé R; Garnero P; van der Heijde D; van der Linden S; Geusens P
Rheumatology (Oxford); 2008 Aug; 47(8):1219-22. PubMed ID: 18539620
[TBL] [Abstract][Full Text] [Related]
20. A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in rheumatoid arthritis.
Ben Achour W; Bouaziz M; Mechri M; Zouari B; Bahlous A; Abdelmoula L; Laadhar L; Sellami M; Sahli H; Cheour E
Libyan J Med; 2018 Dec; 13(1):1512330. PubMed ID: 30160204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
